Chekutanga uye Chete Pedzisa Kwenguva Yakareba Kuita Majekiseni Ekurapa HIV

Makambani eJanssen Pharmaceutical Companies aJohnson & Johnson nhasi azivisa US Food and Drug Administration (FDA) yabvumidza kuvandudzwa kweCABENUVA (cabotegravir uye rilpivirine), ichipa vashandi vehutano uye vanhu vanorarama nehutachiona hwehuman immunodeficiency virus (HIV-1) muUS. sarudzo yekutanga iyi kamwe chete pamwedzi kana mwedzi miviri yega yega pasina kudiwa kwe oral lead-in phase (daily cabotegravir uye rilpivirine mapiritsi, anotorwa kwemwedzi mumwe chete majekiseni ecabotegravir nerilpivirine atangwa). Data yekiriniki yakaratidza iyo regimen inoratidza yakafanana chengetedzo uye efficacy profile zvese uye pasina nemuromo lead-in nguva. CABENUVA yakagadziridzwa pamwe chete sechikamu chemubatanidzwa neViiV Healthcare uye inovaka pakuzvipira kwaJanssen kwemakumi emakore ekurwisa HIV.

"Tine nhoroondo yakaratidza yekuunza marapirwo matsva kuvanhu vanorarama neHIV, uye kuzvipira kwedu kusimudzira budiriro yesainzi hakuna kuzununguka," akadaro James Merson, Ph.D., Global Therapeutic Area Head, Infectious Diseases, Janssen Research. & Development, LLC. "Nechiitiko ichi chakawedzerwa, Janssen ari kupa imwe nzira inorerutsa nzvimbo yekurapa kune vanhu vanorarama neHIV muUS vanonyorerwa kurapwa neCABENUVA."

CABENUVA ndiyo yekutanga uye yega yakazara-yakareba-inobata chirongwa chekurapa HIV uye inotenderwa muUS semushonga kamwe chete pamwedzi kana mwedzi miviri yeHIV-1 muvanhu vakuru vakadzvinyirirwa nehutachiona (HIV-1 RNA <50 copies/mL) pachirongwa chakatsiga chemushonga wemushonga weHIV usina nhoroondo yekukundikana kwekurapa uye pasina kuzivikanwa kana kufungidzirwa kuramba kune cabotegravir kana rilpivirine. Iine ViiV Healthcare's cabotegravir yakawedzerwa-kuburitsa jekiseni rekumiswa mubhodhoro redozi rimwechete uye rilpivirine yakawedzerwa-kuregedzerwa jekiseni rekare mubhodhoro rimwe chete, chigadzirwa cheJanssen Sciences Ireland Unlimited Company, imwe yeJanssen Pharmaceutical Companies of Johnson & Johnson.

"KuJanssen, tinodada nekuenderera mberi nekusimudzira sarudzo dzinotsigira varwere uye kubatsira varapi vehutano mukutsvaga zvirongwa zvekurapa zvemunhu zvinogadzirisa zvidikanwi zvevanhu vanorarama neHIV," akadaro Candice Long, Mutungamiriri, Zvirwere Zvinotapukira & Vaccines, Janssen Therapeutics. , Chikamu cheJanssen Zvigadzirwa, LP. "Kupa huwandu hwakasiyana hwekurapa kweHIV kwakakosha kubatsira kusangana nezvinodiwa zvakasiyana-siyana zvekurapwa, uye tinotenda kuti CABENUVA isarudzo ine musoro kune varwere nevapi vatinoshandira."

Mvumo iyi yeUS FDA inobva paFLAIR (First Long-Acting Injectable Regimen) Vhiki 124 zvawanikwa, izvo zvakaratidza kuti pane zvakabuda zvakafanana maererano nekuchengetedza virologic suppression, kuchengetedzwa, kushivirira uye pharmacokinetics muvanhu vanotanga majekiseni ecabotegravir nerilpivirine nemuromo kana pasina. lead-in.